Abikem 250mg Tablets
PDF Leaflet Revision Date: 15 March 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of metastatic castration-resistant prostate cancer.
Dosage (summary)
1,000 mg (four 250 mg tablets) once daily, taken without food.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may harm a developing fetus.
Key Drug Interactions
- Avoid strong CYP3A4 inducers
- Contraindicated with rifampicin
Contraindications
- Hypersensitivity
- Pregnancy
- Moderate to severe hepatic impairment
- Concomitant use with Ra-223
Common side effects
- Fluid retention
- Hypokalaemia
- Hypertension
- Increased liver enzymes
Counselling Points
- Take at least 2 hours after eating
- Monitor for signs of liver toxicity
- Use condoms if sexually active with women of childbearing age
Serious warnings
- May cause hypertension, hypokalaemia, fluid retention
- Risk of hepatotoxicity
Important Disclaimer
The Abikem 250mg Tablets professional information leaflet below is the property of Ascend Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
